Welcome to our dedicated page for Novo-Nordisk A/S SEC filings (Ticker: NVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Novo Nordisk A/S (NVO) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a foreign private issuer listed on the New York Stock Exchange. Novo Nordisk files reports on Form 6‑K that cover financial performance, pipeline progress, governance changes, and material corporate developments.
For a pharmaceutical preparation manufacturer focused on diabetes, obesity, and rare diseases, these filings are a key source of detail on GLP‑1 and semaglutide programs, including Wegovy injection and the Wegovy pill, as well as investigational assets such as CagriSema and cagrilintide. The 6‑K for the first nine months of 2025, for example, outlines sales growth in diabetes and obesity care, rare disease performance, R&D pipeline highlights, and strategic acquisitions in MASH and rare blood disorders.
Investors can also use Novo Nordisk’s filings to monitor capital markets and governance information. Recent 6‑Ks disclose insider transactions in Novo Nordisk B shares by board members and executives, the convening of an Extraordinary General Meeting to elect new board members, and subsequent changes in board leadership and committee composition. Other filings describe agreements with the US Administration on pricing and access for semaglutide medicines in Medicare and Medicaid, and an unsolicited proposal to acquire Metsera, Inc.
On Stock Titan, these filings are updated as they are released on EDGAR. AI‑powered summaries help explain lengthy financial reports and company announcements in plain language, highlighting items such as revenue drivers in diabetes and obesity care, progress in MASH and cardiovascular programs, and the potential impact of pricing agreements. Users can quickly scan Form 6‑K disclosures, identify insider share dealings, and understand how Novo Nordisk’s strategic decisions and R&D investments may shape its long‑term profile in diabetes, obesity, rare disease, and cardiometabolic medicine.
Novo Nordisk A/S reports progress on its ongoing share repurchase programme. The company plans to buy back up to DKK 15 billion of B shares over a 12‑month period beginning 4 February 2026, including a sub-programme of up to DKK 3.8 billion running to 4 May 2026.
As of 1 April 2026, Novo Nordisk has repurchased 9,967,992 B shares at an average price of DKK 259.47, for a total of DKK 2,586,404,548. The company now holds 27,357,791 B shares as treasury shares, equal to 0.6% of its total share capital of 4,465,000,000 A and B shares.
Novo Nordisk A/S reports progress on its ongoing share repurchase programme. Since 4 February 2026, the company has bought back 9,162,992 B shares at an average price of DKK 261.91, for a total of DKK 2,399,878,368.
This activity is part of a broader plan to repurchase up to DKK 15 billion of B shares over 12 months from 4 February 2026. Following the latest transactions, Novo Nordisk holds 26,552,791 B shares as treasury shares, equal to 0.6% of its 4,465,000,000 total A and B shares.
Novo Nordisk A/S has updated and restated its Articles of Association following approval at the Annual General Meeting on 26 March 2026. The Articles set the company’s share capital at DKK 446,500,000, divided into A share capital of DKK 107,487,200 and B share capital of DKK 339,012,800, with shares of DKK 0.01 or multiples.
A shares are non-negotiable, may have share certificates and carry 10 votes per DKK 0.01, while B shares are negotiable, issued through a central securities depository and carry 1 vote per DKK 0.01. Detailed pre‑emptive rights and transfer restrictions apply to A shares, whereas B shares are freely transferable.
Until 1 April 2028, the Board of Directors is authorised to increase the share capital by up to a nominal DKK 44,650,000, both with and without pre‑emptive rights, mainly via B shares at market price and potentially for non‑cash contributions. The Articles also describe general meeting procedures, allow partially or fully electronic meetings, define a Board of 4–10 shareholder‑elected members plus employee representatives, and formalise an indemnification scheme for directors and executive management. Dividend distribution gives priority returns to A and then B shares, and in a dissolution B share capital is repaid at nominal value before A share capital, with any remaining proceeds shared proportionally.
Novo Nordisk reports that the US FDA has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly long-acting basal insulin for adults with type 2 diabetes, used along with diet and exercise to improve blood sugar control.
The approval is based on the ONWARDS phase 3a programme in about 2,680 adults, where once-weekly Awiqli® was compared with daily basal insulin and met its primary goal of lowering HbA1c, with an overall safety profile consistent with the basal insulin class.
Novo Nordisk plans to launch Awiqli® in the FlexTouch® device in the US in the second half of 2026. Awiqli® is now approved in the US, EU and 13 additional countries, expanding the company’s diabetes treatment portfolio.
Novo Nordisk A/S held its Annual General Meeting, where shareholders approved the statutory Annual Report 2025 and the distribution of profits. The total dividend for 2025 was set at DKK 11.70 per A and B share, consisting of an interim dividend of DKK 3.75 already paid in August 2025 and a final dividend of DKK 7.95 to be paid in March 2026.
Shareholders re-elected Cees de Jong as vice chair and several existing board members, and elected Helena Saxon, Jan van de Winkel and Ramona Sequeira to the Board. Deloitte was re-appointed as auditor.
The Board received authorisation until the 2027 AGM to repurchase up to 10% of the share capital, subject to a 10% holding limit, and an extension to increase share capital until 1 April 2028 by up to nominally DKK 44,650,000. Committee compositions were updated, and Poul Weihrauch will join as a Board observer with the intention of nomination in 2027.
Novo Nordisk A/S provides an update on its ongoing share repurchase programme. The company plans to buy back B shares for up to DKK 15 billion during a 12‑month period beginning 4 February 2026, including a sub-programme of up to DKK 3.8 billion running from 4 February 2026 to 4 May 2026.
As of 20 March 2026, Novo Nordisk has repurchased a total of 7,847,992 B shares at an average price of DKK 266.53 per share, for a total transaction value of DKK 2,091,696,255. Following these transactions, Novo Nordisk holds 25,237,791 B shares as treasury shares, equal to 0.6% of the 4,465,000,000 A and B shares outstanding, including treasury shares.
Novo Nordisk reports that the US FDA has approved Wegovy® HD, a once-weekly injectable semaglutide 7.2 mg dose, to reduce excess body weight and maintain long-term weight reduction. The FDA also granted a Commissioner’s National Priority Voucher, highlighting the therapy’s importance for US health priorities.
The accelerated approval is supported by the STEP UP phase 3 programme. In the STEP UP trial in adults with obesity, semaglutide 7.2 mg delivered a 20.7% mean weight loss, and 31.2% of participants achieved at least 25% weight loss. In the STEP UP T2D trial in adults with obesity and type 2 diabetes, mean weight loss reached 14.1%. Safety and tolerability were consistent with the known profile of semaglutide.
Novo Nordisk plans to launch Wegovy® HD in a single-dose pen in the US in April 2026. The 7.2 mg dose is already approved for adults with obesity in the EU and UK, and regulatory decisions on the single-dose pen in those regions are expected in the second half of 2026.
Novo Nordisk A/S provides an update on its ongoing share repurchase programme. The company plans to buy back up to DKK 15 billion of B shares over the 12‑month period starting 4 February 2026, including up to DKK 3.8 billion between 4 February and 4 May 2026.
As of 13 March 2026, Novo Nordisk has repurchased 6,577,992 B shares at an average price of DKK 271.14, for a total of DKK 1,783,540,174. After these transactions, it holds 23,967,791 B shares as treasury shares, equal to 0.5% of its 4,465,000,000 total A and B shares.
Novo Nordisk A/S reports progress on its 2026 share repurchase programme. As part of a broader plan to buy back up to DKK 15 billion of B shares over 12 months from 4 February 2026, the company has been actively repurchasing shares in early March.
As of 6 March 2026, Novo Nordisk has repurchased 5,334,992 B shares at an average price of DKK 276.06, for a total of DKK 1,472,797,094. Following these transactions, it holds 22,724,791 B shares as treasury shares, equal to 0.5% of its total 4,465,000,000 A and B shares.
Novo Nordisk A/S reports that its employees have completed the election of new employee representatives to the company’s Board of Directors. These representatives are elected for a four-year term and, under Danish law, employee-elected members may make up half of the shareholder-elected board members.
The newly elected employee representatives will join the Board after the annual general meeting on 26 March 2026, when current employee board members Liselotte Hyveled and Tanja Villumsen, who did not run for re-election, will step down. Employee-elected directors have the same rights and responsibilities as shareholder-elected directors.